李寧(02331.HK):期權生效
格隆匯 12 月 23日丨李寧(02331.HK)公佈,有關股份轉讓協議及期權協議,據此,全資附屬上海悦奧體育用品有限公司作為賣方向非凡中國出售紅雙喜集團10%股權,及買方獲授認沽期權以向賣方出售紅雙喜集團10%股權及衍生權益。
根據期權協議的條款及條件,由於賣方及買方均無於行使日期(即2020年12月22日)或之前通過書面通知的形式行使有關期權,故此根據期權協議,期權已自動失效。
鑑於目前市況及紅雙喜前景不明朗,公司董事認為,不行使認購期權(i)可允許公司將需要預留的用於支付認購期權行使價的金額,用於其他更有價值之投資及(ii)屬公平合理,且符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.